The next chapter of radiopharmaceutical therapy starts now

Leading-edge technologies in the fight against cancer

We are a next generation radiopharmaceutical company, taking cancer head on.

For what’s ahead

Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.

What to expect

Treatments in development

We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.

About our Pipeline

Focused treatment

With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.

Learn the science

Clinical trials

Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.

Splash trial

News + Stories

Press Release
27 Mar
2023

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates. Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023.

Press Release
7 Mar
2023

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays.